US Drug Recall Register

FDA Drug Recalls

14,450 recalls · Class II, newest first

Class II · Moderate risk Ongoing

Hydrogen Peroxide Oral Rinse

Reason CGMP Deviations: products may not conform to the labeled specifications.

Den-Mat Holdings, LLC NDC 59883-202-16 D-0287-2024
Class II · Moderate risk Ongoing

OralProCare medicated lip treatment

Reason CGMP Deviations: products may not conform to the labeled specifications.

Den-Mat Holdings, LLC NDC 59883-500-01 D-0286-2024
Class II · Moderate risk Terminated

Phenoxybenzamine Hydrochloride Capsules

Reason Failed Impurities/Degradation Specifications: Out of specification for unknown impurity.

Amneal Pharmaceuticals of New York, LLC NDC 60219-1502-01 D-0319-2024
Class II · Moderate risk Terminated

Budesonide Extended-Release Tablets

Reason Failed Dissolution Specifications

Golden State Medical Supply Inc. NDC 51407-824-30 D-0276-2024
Class II · Moderate risk Terminated

Rifampin Capsules USP

Reason Failed Impurities/Degradation Specification.

Amerisource Health Services LLC D-0285-2024
Class II · Moderate risk Ongoing

Vasostrict

Reason Superpotent Drug: Assay from the 3-month and 6-month stability intervals exceeded the upper specification limit.

Par Sterile Products LLC D-0232-2024
Class II · Moderate risk Ongoing

Medline Remedy Clinical TREAT Antifungal Cream

Reason Labeling: Not Elsewhere Classified; Product labeling contains the claim of 'Paraben Free' while the product does in fact contain parabens as part of the formulation/ ingredient list.

MEDLINE INDUSTRIES, LP - Northfield D-0315-2024
Class II · Moderate risk Terminated

Fosaprepitant for Injection 150 mg per vial

Reason Lack of Sterility Assurance: Aseptic process simulation failure.

Be Pharmaceuticals Ag NDC 71839-104-01 D-0262-2024
Class II · Moderate risk Terminated

Rifampin Capsules USP 300mg

Reason Subpotent Drug and Failed Impurities/Degradation Specifications

Lupin Pharmaceuticals Inc. NDC 68180-659-06 D-0284-2024
Class II · Moderate risk Terminated

Rifampin Capsules USP 150mg

Reason Subpotent Drug and Failed Impurities/Degradation Specifications

Lupin Pharmaceuticals Inc. NDC 68180-658-06 D-0283-2024
Class II · Moderate risk Terminated

Fluocinolone Acetonide Oil

Reason Failed Excipient Specifications: OOS for assay of Isopropyl Alcohol

Glenmark Pharmaceuticals Inc., USA NDC 68462-185-56 D-0259-2024
Class II · Moderate risk Terminated

Cefixime for Oral Suspension 100mg/5mL

Reason Failed Impurities/Degradation Specifications

Lupin Pharmaceuticals Inc. NDC 68180-405-01 D-0274-2024
Class II · Moderate risk Completed

Tizanidine Tablets

Reason Presence of Foreign tablets/capsules - identified as tizanidine 2 mg tablets.

Dr. Reddy's Laboratories, Inc. NDC 55111-180-15 D-0223-2024
Class II · Moderate risk Terminated

Methoxsalen Capsules

Reason Failed Dissolution Specifications

Strides Pharma Inc. NDC 64380-752-16 D-0260-2024
Class II · Moderate risk Ongoing

Ibuprofen and Famotidine Tablets 800mg/26.6mg

Reason Presence of Foreign Tablet/Capsule: A stray Rasagiline Mesylate 1 mg tablet was discovered in an unopened bottle of Ibuprofen and Famotidine.

Ascend Laboratories, LLC NDC 67877-626-90 D-0237-2024
Class II · Moderate risk Ongoing

Quality Choice No Drip Severe Congestion Nasal Pump Mist

Reason CGMP Deviations: Firm reported possible microbial contamination in the purified water used in the manufacturing of the products. No contamination was found in the final products.

Seaway Pharma Inc. NDC 63868-608-01 D-0217-2024
Class II · Moderate risk Ongoing

Quality Choice No Drip Extra Moisturizing Nasal Pump Mist…

Reason CGMP Deviations: Firm reported possible microbial contamination in the purified water used in the manufacturing of the products. No contamination was found in the final products.

Seaway Pharma Inc. NDC 63868-676-01 D-0216-2024
Class II · Moderate risk Ongoing

Premier Value Tussin Cough DM

Reason CGMP Deviations: Firm reported possible microbial contamination in the purified water used in the manufacturing of the products. No contamination was found in the final products.

Seaway Pharma Inc. D-0215-2024
Class II · Moderate risk Ongoing

Nasal Spray Original No Drip Oxymetazoline HCl Nasal Solution

Reason CGMP Deviations: Firm reported possible microbial contamination in the purified water used in the manufacturing of the products. No contamination was found in the final products.

Seaway Pharma Inc. NDC 63868-607-01 D-0214-2024